Apolipoprotein A-II: Still second fiddle in high-density lipoprotein metabolism?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages 166-167

  Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

apolipoprotein A II; atherosclerosis; cholesterol; Editorials; high density lipoprotein

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; EDITORIAL; HEPATITIS; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOOTH MUSCLE;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEIN A-II; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MALE;

EID: 84872941532     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300921     Document Type: Editorial

References (18)

1. Segrest JP, Garber DW, Brouillette CG, Harvey SC, Anantharamaiah GM. The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem. 1994;45:303-369.
2. Johnson WJ, Kilsdonk EP, van Tol A, Phillips MC, Rothblat GH. Cholesterol effux from cells to immunopurifed subfractions of human high density lipoprotein: LP-AI and LP-AI/AII. J Lipid Res. 1991;32:1993-2000.
3. Huang Y, von Eckardstein A, Wu S, Assmann G. Cholesterol effux, cholesterol esterifcation, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol. 1995;15:1412-1418.
4. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
5. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in trans-genic mice. Nature. 1993;365:762-764.
6. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116:2029-2035.
7. Xiao J, Zhang F, Wiltshire S, Hung J, Jennens M, Beilby JP, Thompson PL, McQuillan BM, McCaskie PA, Carter KW, Palmer LJ, Powell BL. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population. Atherosclerosis. 2008;199:333-339.
8. Deeb SS, Takata K, Peng RL, Kajiyama G, Albers JJ. A splice-junction mutation responsible for familial apolipoprotein A-II defciency. Am J Hum Genet. 1990;46:822-827.
9. Wang Y, Niimi M, Nishijima K, et al. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2012;33:224-231.
10. Brousseau ME, Hoeg JM. Transgenic rabbits as models for atherosclerosis research. J Lipid Res. 1999;40:365-375.
11. Brousseau ME, Kauffman RD, Herderick EE, Demosky SJ Jr, Evans W, Marcovina S, Santamarina-Fojo S, Brewer HB Jr, Hoeg JM. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:450-458.
12. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipo-protein: it's not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22:9-15.
13. Bailey D, Jahagirdar R, Gordon A, Hafane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580-2589.
14. Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008;6:1203-1215.
15. Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT. 5A apolipoprotein mimetic peptide promotes cholesterol effux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334:634-641.
16. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2007;8:201-212.
17. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, Brewer HB Jr. Apolipoprotein specifcity for lipid effux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001;280:818-823.
18. Yamashita J, Iwamura C, Sasaki T, Mitsumori K, Ohshima K, Hada K, Hara N, Takahashi M, Kaneshiro Y, Tanaka H, Kaneko K, Nakayama T. Apolipoprotein A-II suppressed concanavalin A-induced hepatitis via the inhibition of CD4 T cell function. J Immunol. 2011;186:3410-3420.